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ABSTRACT
The cyclopentenone prostaglandin and PPAR agonist 15-de-
oxy-12,14-prostaglandin J2 (15d-PGJ2) displays anti-inflam-
matory effects in several experimental models. Direct modifi-
cation of protein thiols is arising as an important mechanism of
cyclopentenone prostaglandin action. However, little is known
about the extent or specificity of this process. Mesangial cells
(MC) play a key role in glomerulonephritis. In this work, we have
studied the selectivity of protein modification by 15d-PGJ2 in
MC, and the correlation with the modulation of several pro-
inflammatory genes. MC incubation with biotinylated 15d-PGJ2
results in the labeling of a distinct set of proteins as evidenced
by two-dimensional electrophoresis. 15d-PGJ2 binds to nu-
clear and cytosolic targets as detected by fluorescence micros-
copy and subcellular fractionation. The pattern of biotinylated
15d-PGJ2-modified polypeptides is readily distinguishable
from that of total protein staining or labeling with biotinylated
iodoacetamide. 15d-PGJ2 addition requires the double bond in
the cyclopentane ring. 9,10-Dihydro-15d-PGJ2, a 15d-PGJ2
analog that shows the same potency as peroxisome prolifera-
tor-activated receptor (PPAR) agonist in MC but lacks the
cyclopentenone moiety, displays reduced ability to modify pro-
teins and to block 15d-PGJ2 binding. Micromolar concentrations
of 15d-PGJ2 inhibit cytokine-elicited levels of inducible nitric-
oxide synthase, cyclooxygenase-2, and intercellular adhesion
molecule-1 in MC. In contrast, 9,10-dihydro-15d-PGJ2 does
not reproduce this inhibition. 15d-PGJ2 effect is not blocked
by the PPAR antagonist 2-chloro-5-nitro-N-phenylbenz-
amide (GW9662). Moreover, compounds possessing an
,-unsaturated carbonyl group, like 2-cyclopenten-1-one and
2-cyclohexen-1-one, reduce pro-inflammatory gene expression.
These observations indicate that covalent modification of cellular
thiols by 15d-PGJ2 is a selective process that plays an important
role in the inhibition of MC responses to pro-inflammatory stimuli.
Cyclopentenone prostaglandins (cyPG) are endogenous
prostanoids that arise from the dehydration of their parent
PG. Thus, dehydration of PGE2 gives rise to PGA2, whereas
cyPG of the J series, like PGJ2 and 15-deoxy-
12,14-PGJ2
(15d-PGJ2), arise from the dehydration of PGD2. The gener-
ation of 15d-PGJ2 has been reported to increase under situ-
ations associated with COX-2 induction, such as inflamma-
tory processes (Gilroy et al., 1999). 15d-PGJ2 has been the
subject of considerable study because of its identification as a
ligand of the transcription factors known as peroxisome pro-
liferator-activated receptors (PPAR), which are involved in
the control of lipid metabolism and immune response (For-
man et al., 1995). During the course of these studies it has
been realized that 15d-PGJ2 may modulate multiple cellular
functions by mechanisms dependent and independent of
PPAR.
15d-PGJ2 displays anti-inflammatory and protective ef-
fects against several types of injury both in cellular systems
and in animal models (Rovin et al., 2001; Cuzzocrea et al.,
2002; Ianaro et al., 2003b; Zingarelli et al., 2003). 15d-PGJ2
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has been reported to attenuate the development of acute and
chronic inflammation (Cuzzocrea et al., 2002) and to amelio-
rate the symptoms of septic shock (Zingarelli et al., 2003). In
addition, micromolar concentrations of cyPG have been found
to inhibit the expression of several pro-inflammatory genes
including monocyte chemoattractant protein-1, matrix met-
alloproteinase-9, or inducible nitric-oxide synthase (iNOS)
(Ricote et al., 1998; Reilly et al., 2001; Rovin et al., 2001).
Although the pathophysiological importance of these findings
is not clear at present, they can be of pharmacological rele-
vance, because the elucidation of the mechanisms involved in
the protective effects of cyPG could aid in the identification of
potential targets for development of anti-inflammatory strat-
egies. CyPG may modulate multiple cellular processes, in-
cluding PPAR activation, generation of reactive oxidative
species, induction of a heat shock response, and expression of
proteins involved in cellular defense mechanisms, such as
heme oxygenase (Straus and Glass, 2001). In addition, cyPG
can directly modify cellular proteins. CyPG possess an ,-
unsaturated carbonyl group in the cyclopentane ring that can
form covalent adducts with free thiols in glutathione or in
proteins by Michael addition. This may result in the alter-
ation of cellular redox status and/or in the modulation of
protein function. Several proteins have been identified which
can be covalently modified by 15d-PGJ2. Some of these pro-
teins are involved in the modulation of inflammation, includ-
ing several components of the NF-B (Castrillo et al., 2000;
Rossi et al., 2000; Straus et al., 2000; Cernuda-Morollo´n et
al., 2001) and AP-1 activation pathways (Pe´rez-Sala et al.,
2003), and proteins involved in the regulation of transcrip-
tion factor activity by redox changes or electrophiles (Moos et
al., 2003; Shibata et al., 2003; Itoh et al., 2004; Levonen et al.,
2004). Therefore, the mechanisms operating in a given in-
flammatory situation may be multiple and depend on several
factors like the structure and concentration of the cyPG, the
cell type, and the nature of the inflammatory stimuli.
MC play an important role in glomerulonephritis because
they are a source for inflammatory mediators, and key play-
ers in the production and turnover of extracellular matrix
and in the interaction with leukocytes (Mene´, 1996). MC
express iNOS and cyclooxygenase-2 (COX-2) in response to
pro-inflammatory agents, which are responsible for an in-
creased generation of NO and prostaglandins (Rzymkiewicz
et al., 1994; Saura et al., 1995). In their activated state, MC
can also release cytokines that contribute to glomerular in-
jury and express a variety of chemokines, integrins, and
adhesion molecules, like intercellular adhesion molecule-1
(ICAM-1), which play a pivotal role in leukocyte infiltration
(Satriano et al., 1997). For these reasons, MC constitutes a
relevant cellular model of inflammation. In this study, we
illustrate the covalent modification of MC proteins by 15d-
PGJ2 and explore the contribution of this mechanism to the
modulation of cytokine-elicited changes in the expression
levels of the pro-inflammatory genes iNOS, COX-2, and
ICAM-1.
Materials and Methods
Materials. 15-Deoxy-12,14-prostaglandin J2 was from Calbio-
chem-Novabiochem (San Diego, CA) or from Cayman Chemical (Ann
Arbor, MI). 9,10-Dihydro-15-deoxy-12,14-prostaglandin J2 (9,10-di-
hydro-15d-PGJ2), PGE2, and T0070907 were from Cayman Chemi-
cal. Rosiglitazone was from Alexis Biochemicals. Recombinant hu-
man IL-1 (5  107 U/mg) was from Roche Diagnostics S. L.
(Barcelona, Spain). Recombinant human TNF- was from Serotec
(Oxford, UK). Polyclonal anti-iNOS and anti-c-Jun were from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-COX-2 antibody was
from Oxford Biomedical Research and anti-ICAM-1 was from R&D
Systems (Minneapolis, MN). Horseradish peroxidase (HRP) conju-
gated anti-rabbit immunoglobulins were from DakoCytomation
(Glostrup, Denmark). HRP-conjugated streptavidin and enhanced
chemiluminescence (ECL) reagents were from Amersham Bio-
sciences (Barcelona, Spain). Cell culture media and supplements
were from Invitrogen S.A. (Barcelona, Spain). GelCode Blue Coomas-
sie staining was from Pierce (Rockford, IL). All other reagents used
were of the highest purity available from Sigma Chemical Co. (St.
Louis, MO).
Cell Culture and Treatments. Rat mesangial cells were ob-
tained as reported earlier (Saura et al., 1995). Cells were grown in
RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM glu-
tamine, 100 U/ml penicillin, and 100 g/ml streptomycin. For exper-
iments, passages 7 to 18 were used. Confluent MC were incubated in
serum-free medium for 24 h before experiments. For cytokine stim-
ulation, cells were treated with a combination of 3 ng/ml IL-1 plus
37 ng/ml TNF- in serum-free medium without phenol red. PPAR
agonists, 2-cyclopenten-1-one (cyclopentenone) and 2-cyclohexen-1-
one (cyclohexenone) were dissolved in DMSO and added to cultures
2 h before cytokine stimulation. GW9662 and T0070907 were added
in DMSO 30 min before PPAR agonists. Final DMSO concentration
was 0.1% (v/v). Cells not treated with agonists received an equivalent
volume of DMSO. iNOS activity was estimated from the accumula-
tion of nitrite in the cell medium using the Griess method (Saura et
al., 1995). Levels of the protein of interest were assessed by Western
blot as described previously (Cernuda-Morollo´n et al., 2002). The
levels of cellular actin were used as a control for intersample vari-
ability. None of the compounds used elicited pro-inflammatory gene
expression in the absence of cytokines.
Plasmids and Transient Transfections. The PPAR reporter
construct p4xAco-Luc, described in (He et al., 1999), was the gener-
ous gift of Drs. B. Vogelstein and K. W. Kinzler. To assess PPAR
activity, preconfluent rat mesangial cells were incubated for 3 h in
transfection mixture containing 1 g of 4xAco-Luc or empty vector
(pBV-Luc) and 5 ng of pSG5-Renilla in Opti-MEM medium, in the
presence of LipofectAMINE 2000 Reagent (Invitrogen). After a 4-h
recovery period in serum-free medium, cells were treated with the
indicated agents. The activities of firefly and Renilla reniformis
luciferases present in cell lysates were measured using a dual lucif-
erase reporter assay system from Promega (Madison, WI). All assays
were done in duplicate and results are expressed as the ratio be-
tween firefly and R. reniformis luciferase activities.
Fluorescence Microscopy. 15d-PGJ2 biotinylated at the car-
boxyl group was generously provided by Dr. F. J. Can˜ada. To visu-
alize the subcellular distribution of 15d-PGJ2 binding sites, cells
were grown on glass coverslips. Subconfluent MC were incubated for
15 min in the presence of 10 M biotinylated 15d-PGJ2 or vehicle
(DMSO) in serum-free medium. After incubation, coverslips were
washed several times with PBS and cells were fixed by a 15-min
incubation with 3.5% formaldehyde and permeabilized by incubation
with 0.05% Triton X-100 for 10 min. Coverslips were subsequently
washed with PBS, incubated for 20 min with 1% (w/v) bovine serum
albumin in PBS, and with 1 g/ml Alexa488-streptavidin (Molecular
Probes Inc., Eugene, OR) for 30 min. To visualize cell nuclei, cover-
slips were incubated with 0.2 g/ml DAPI (Molecular Probes) for 20
min. After extensive washing, coverslips were allowed to dry and
mounted with Fluorsafe (Calbiochem-Novabiochem). Fluorescence
was observed with a Zeiss microscope connected to a charge-coupled
device camera.
Incorporation of Biotinylated 15d-PGJ2 into MC Proteins.
MC were incubated with biotinylated 15d-PGJ2 for 2 h in serum-free
medium. Total cells lysates were obtained by disrupting cells in 50
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mM Tris, pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.1 mM -mercap-
toethanol, 0.5% SDS containing 2 g/ml of each of the protease
inhibitors: leupeptin, pepstatin A, and aprotinin. Nuclear and cyto-
solic extracts were obtained as described previously (Cernuda-Morol-
lo´n et al., 2001). Protein concentration was determined by the BCA
protein assay from Pierce (Rockford, IL). Fifteen microgram of pro-
tein from each experimental condition were electrophoresed on
12.5% polyacrylamide gels and transferred to Immobilon-P mem-
branes (Millipore, Bedford, MA). For two dimensional electrophore-
sis, cells were lysed in 20 mM HEPES, pH 7.2, 50 mM NaCl, 1%
Nonidet P-40, 0.3% sodium deoxycholate, and 0.1% SDS plus pro-
tease inhibitors. Aliquots of cell lysates containing 100 g of protein
were precipitated with 10% TCA, resuspended in 130 l of IEF
sample buffer (4% Triton X-100, 2 M thiourea, 7 M urea, 100 mM
dithiothreitol, and 2% Bio-lyte ampholytes) and loaded on Ready-
Strip IPG Strips (pH 3–10; Bio-Rad) for isoelectric focusing on a
Protean IEF cell (Bio-Rad), following the instructions of the manu-
facturer. For the second dimension, strips were equilibrated and
loaded on 15% polyacrylamide SDS gels. Incorporation of biotinyl-
ated 15d-PGJ2 into MC proteins was assessed by Western blot and
detection with HRP-conjugated streptavidin and ECL, as described
previously (Oliva et al., 2003; Pe´rez-Sala et al., 2003).
Binding of 15d-PGJ2 to Proteins in Vitro. The ability of bio-
tinylated 15d-PGJ2 to form covalent adducts with proteins was ex-
plored in vitro by using total cell lysates or recombinant human
c-Jun DNA binding domain as a model peptide by a Western blot
assay, essentially as described previously by us (Pe´rez-Sala et al.,
2003). The linearity of the detection of incorporated biotin was en-
sured by using a biotinylated BSA standard (Pierce). The formation
of 15d-PGJ2- or 9,10-dihydro-15d-PGJ2-c-Jun adducts was assessed
by MALDI-TOF mass spectrometry analysis as described previously
(Pe´rez-Sala et al., 2003). In brief, peptides were purified by ZipTip
C18 (Millipore, Bedford, MA). The laser desorption/ionization exper-
iments were performed on a BIFLEX III time-of-flight instrument
(Bruker-Franzen Analytik, Bremen, Germany) operated in the pos-
itive mode. A saturated solution of sinapinic acid in acetonitrile/
water (1:2) with 0.1% trifluoroacetic acid was used as the matrix.
Equal volumes (0.5 l) of the sample solution and the matrix were
spotted on the target and air-dried. External calibration was per-
formed, using the protein calibration standard II (Bruker Daltonics,
Bremen, Germany), and samples were analyzed in the linear mode.
Statistical Analysis. Results are expressed as mean  S.E.M.
Statistical analysis was performed with the use of the unpaired
two-tailed Student’s t test or analysis of variance where applicable.
Comparisons were considered statistically significant at the p 0.05
level.
Results
15d-PGJ2 Binds to Multiple Protein Targets in MC.
CyPG may exert their effects by forming covalent adducts
with cellular proteins. To assess the extent of protein modi-
fication in MC, we analyzed total lysates from cells incubated
with 15d-PGJ2 or biotinylated 15d-PGJ2 by two-dimensional
electrophoresis (Fig. 1). Western blot analysis of the two-
dimensional gels showed the presence of several spots corre-
sponding to endogenous biotinylated proteins in the lysates
from cells treated with 15d-PGJ2 (Fig. 1A). In gels from cells
treated with biotinylated 15d-PGJ2, we could detect at least
50 additional spots (Fig. 1B). The same labeling pattern was
obtained in several experiments using different batches of
cells. Total protein staining revealed over 350 spots. The
biotin-positive spots did not coincide with the major proteins
detected by Coomassie staining. These observations indicate
that biotinylated 15d-PGJ2 can bind to a defined set of tar-
gets in MC and this binding is determined by factors other
than protein abundance.
15d-PGJ2 Binds to Proteins Distributed in Nuclear
and Cytosolic Compartments in MC. To date, a limited
number of proteins that can be modified by cyPG have been
identified using several experimental systems. To obtain a
deeper knowledge of the cellular targets for 15d-PGJ2 addi-
tion, we explored the distribution of the sites for covalent
attachment of biotinylated 15d-PGJ2 in MC by fluorescence
microscopy. Incubation of MC in the presence of 10 M bio-
tinylated 15d-PGJ2 led to the incorporation of the modified
PG into various cellular structures as detected with fluores-
cent streptavidin (Fig. 2A). The labeling pattern obtained
after incubation with biotinylated 15d-PGJ2 was clearly dif-
ferent from that of endogenous biotinylated proteins (Fig. 2A,
vehicle), which showed a perinuclear distribution typical of
mitochondrial localization, as expected for several biotin-
dependent carboxylases (Hollinshead et al., 1997). In con-
trast, biotinylated 15d-PGJ2 was distributed both in cyto-
plasmic and nuclear compartments. The position of cell
nuclei is evidenced by staining with DAPI. To confirm the
presence of both cytoplasmic and nuclear targets for covalent
attachment of biotinylated 15d-PGJ2 in MC, we performed
subcellular fractionation. As depicted in Fig. 2B, incubation
of MC with the biotinylated PG resulted in the incorporation
of biotin into a broad number of polypeptides that could be
detected both in nuclear extracts and in the cytosolic fraction.
The patterns obtained in both fractions were different, show-
Fig. 1. Modification of MC proteins by biotinylated 15d-PGJ2. MC were
incubated with 5 M 15d-PGJ2 or biotinylated 15d-PGJ2 for 2 h. Cell
lysates containing 100 g of protein were analyzed by two-dimensional
electrophoresis and Western blot and by detection with HRP-conjugated
streptavidin. ECL exposures were carried out for 1 min. The Coomassie
staining of a gel run in parallel is shown in C. The position of molecular
weight markers is shown on the left and that of the main endogenous
biotinylated proteins is marked by arrowheads.
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ing the presence of several polypeptides that were enriched
in one of the fractions, some of which are marked by arrow-
heads in Fig. 2B.
Binding of Biotinylated 15d-PGJ2 to Cellular Pro-
teins Is Selective. We next explored the selectivity of pro-
tein modification by biotinylated 15d-PGJ2. Incorporation of
the biotin label into MC polypeptides after incubation of
intact cells with biotinylated 15d-PGJ2 was dose-dependent
(Fig. 3A). Several faint bands could be distinguished above
the background of endogenous biotinylated proteins after
incubation of MC in the presence of 100 nM biotinylated
15d-PGJ2, whereas micromolar concentrations of the biotin-
ylated PG led to evident protein labeling. 15d-PGJ2 can bind
to purified proteins in vitro. We were interested in assessing
the ability of 15d-PGJ2 to modify MC proteins in cell-free
extracts. After incubation of MC lysates with biotinylated
15d-PGJ2, numerous biotin-containing polypeptides could be
detected (Fig. 3B), although the intensity of the labeling was
lower than when incubating intact cells with the same con-
centration of biotinylated 15d-PGJ2. The available evidence
suggests that the reaction of 15d-PGJ2 with protein thiols
does not occur randomly but takes place preferentially at
specific cysteine residues within given proteins. To further
substantiate this point, we compared the labeling pattern
obtained by incubation of cell lysates with biotinylated 15d-
PGJ2 and with biotinylated iodoacetamide, a general cys-
teine-modifying reagent. Incubation of cell lysates with bio-
tinylated iodoacetamide led to the incorporation of biotin into
multiple polypeptide bands in a pattern that closely resem-
bled total protein staining (Fig. 3B) and was readily distin-
guishable from biotinylated 15d-PGJ2-induced protein mod-
ification. These differences were analyzed by image scanning
and quantitation of the blots shown in Fig. 3B. The profiles
obtained, shown in Fig. 3C, clearly illustrate the lack of
coincidence between the main targets for biotinylated 15d-
PGJ2 and biotinylated iodoacetamide incorporation. Taken
together, these observations suggest that binding of biotin-
ylated 15d-PGJ2 occurs at a specific set of cellular proteins
and does not correlate with thiol accessibility.
Importance of the Cyclopentenone Moiety in the
Modification of Protein Targets by 15d-PGJ2. We have
reported previously that c-Jun is a target for 15d-PGJ2 addi-
tion, both in vitro and in intact cells (Pe´rez-Sala et al., 2003).
To explore the structural requirements for protein modifica-
tion by 15d-PGJ2, we performed an in vitro assay using a
peptide from human c-Jun as a model of Michael acceptor.
This peptide contains two cysteine residues; of them, the one
equivalent to cysteine 269 in full-length human c-Jun has
been shown to be the preferential site of modification by
15d-PGJ2 (Pe´rez-Sala et al., 2003). The formation of adducts
between 15d-PGJ2 and the c-Jun peptide was monitored by
MALDI-TOF mass spectrometry (Fig. 4). The control c-Jun
peptide showed a peak m/z  13,479, which corresponds to
the calculated mass of the construct (Pe´rez-Sala et al., 2003).
As we have reported previously, 15d-PGJ2 (mass 316.5 Da)
readily formed an adduct with c-Jun, as indicated by the
appearance of a peak m/z at 13,795. We next explored the
behavior of 9,10-dihydro-15d-PGJ2, a 15d-PGJ2 analog that
lacks the cyclopentenone structure. This analog was de-
signed to retain PPAR agonist activity and to be more re-
sistant to metabolism through conjugation with glutathione,
which has been proposed to occur across the ,-unsaturated
enone, and more specifically through carbon 9 (Paumi et al.,
2003). A peak m/z of 13,802 was detected in the 9,10-dihy-
dro-15d-PGJ2-treated c-Jun sample (Fig. 4), which is compat-
ible with the formation of an adduct between c-Jun and the
9,10-dihydro analog (expected m/z, 13,798). This suggests
that in the absence of the electrophilic carbon in the cyclo-
pentane ring, conjugation can occur through the electrophilic
carbon at position 13. However, this analog is less efficient
than 15d-PGJ2 at forming a Michael adduct with c-Jun, as
estimated from the relative intensity of the corresponding
peaks. As expected, PGE2, which does not possess an unsat-
urated carbonyl group, did not bind to the c-Jun peptide.
We next compared the performance of the various prosta-
noids by using a Western blot-based competition assay. As it
is shown in Fig. 5A, incubation of the c-Jun fragment with
biotinylated iodoacetamide resulted in the incorporation of
the biotin label as detected by Western blot and detection
with HRP-conjugated streptavidin. Preincubation of the c-
Jun construct with 15d-PGJ2 clearly reduced labeling with
biotinylated iodoacetamide (49  3% inhibition, average 
S.E.M. of three assays). 9,10-Dihydro-15d-PGJ2 was much
less effective than 15d-PGJ2 (15  7% reduction), and PGE2
was virtually ineffective. In addition, we observed that the
binding of biotinylated 15d-PGJ2 to c-Jun in vitro was
blocked by the presence of an excess of nonbiotinylated 15d-
PGJ2 (94  6% inhibition, average  S.E.M. of three assays),
Fig. 2. Biotinylated 15d-PGJ2 binds
to nuclear and cytosolic proteins in
MC. A, MC grown on glass coverslips
were incubated with vehicle or 10 M
biotinylated 15d-PGJ2 and biotin-pos-
itive structures were visualized by in-
cubation with Alexa488-streptavidin.
The position of cell nuclei is evidenced
by staining with DAPI, and cell mor-
phology under visible light is shown
at bottom (vis). Images were obtained
at 40 magnification; scale bar, 25
m. B, MC were incubated in the
presence of 5 M 15d-PGJ2 or biotin-
ylated 15d-PGJ2 for 2 h, and the pres-
ence of biotinylated polypeptides in
several cellular fractions was as-
sessed by Western blot and detection
with HRP-streptavidin. Arrowheads
mark the position of bands that seem
enriched in one of the fractions.
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but it was only partially reduced by 9,10-dihydro-15d-PGJ2
(51  14% reduction) and not affected by PGE2 (Fig. 5B).
Consistent with the results shown above, the binding of bio-
tinylated 15d-PGJ2 to proteins in MC lysates was markedly
reduced by the presence of an excess of nonbiotinylated 15d-
PGJ2, whereas 9,10-dihydro-15d-PGJ2 and PGE2 only mod-
erately reduced protein labeling (Fig. 5C). The labeling in the
presence of an excess of 9,10-dihydro-15d-PGJ2, as estimated
from the scanning of several bands, was reduced by 20 to 30%
compared with the labeling in the presence of PGE2, which
does not bind covalently to proteins, whereas 15d-PGJ2 elic-
ited an 80% inhibition. Taken together, these observations
suggest that, although the 9,10-dihydro analog of 15d-PGJ2
can form adducts with proteins to some extent, the double
bond at position 9–10 in the cyclopentane ring of 15d-PGJ2 is
an important determinant for its binding to protein targets.
15d-PGJ2 and 9,10-Dihydro-15d-PGJ2 Activate PPAR
in MC. To use 9,10-dihydro-15d-PGJ2 as a tool to assess the
relative importance of the multiple mechanisms potentially
involved in the effects of 15d-PGJ2 in MC, we compared the
potency of both compounds as PPAR agonists. As shown in
Fig. 6A, 9,10-dihydro-15d-PGJ2 was able to activate PPAR to
the same extent as 15d-PGJ2, as assessed using a luciferase
reporter assay. These results indicate that 15d-PGJ2 and
9,10–15d-PGJ2 are equipotent as PPAR agonists in MC. The
high-affinity PPAR agonist rosiglitazone also activated
PPRE activity, although to a lower extent than 9,10-dihydro-
15d-PGJ2, and this effect was partially blocked by the PPAR
antagonist T0070907 (Lee et al., 2002) (27% reduction of the
rosiglitazone-elicited stimulation; Fig. 6B). In contrast, the
electrophilic compounds cyclopentenone and cyclohexenone
did not activate PPAR (Fig. 6B).
Role of Protein Modification in the Effects of 15d-
PGJ2 on iNOS Induction. iNOS is a key pro-inflammatory
gene that can be modulated by cyPG (Ricote et al., 1998;
Kwon et al., 1999). However, the mechanisms responsible for
their effects have not been fully elucidated. We observed that
micromolar concentrations of 15d-PGJ2 markedly inhibited
both nitrite accumulation and iNOS protein levels in MC
stimulated with IL-1 plus TNF- (Fig. 7A). In contrast,
9,10-dihydro-15d-PGJ2 did not reduce iNOS induction. None
of these compounds modulated nitrite generation or iNOS
levels per se. These results indicate that the double bond at
the 9 position in 15d-PGJ2 is important for its ability to
interfere with iNOS induction. The observation that both
compounds activate PPAR to the same extent makes it un-
likely that the inhibitory effect of 15d-PGJ2 is related to
PPAR activation. In accordance to this, the PPAR antago-
nist GW9662 did not reduce 15d-PGJ2 inhibition of iNOS
induction (Fig. 7B). The PPAR agonist rosiglitazone, which
is not structurally related to 15d-PGJ2, did not inhibit iNOS
levels but increased them (Fig. 7C), although the antagonist
T0070907 did not elicit appreciable changes in this assay. In
addition, the compound cyclopentenone, which mimics only
the cyclopentenone moiety of 15d-PGJ2 and does not activate
PPAR, at concentrations similar to those used in previous
studies (Straus et al., 2000; Cippitelli et al., 2003), effectively
reduced cytokine-elicited iNOS levels (Fig. 8). Moreover, an-
other cyclic electrophile possessing an unsaturated carbonyl
group, but unrelated to 15d-PGJ2, such as cyclohexenone,
blunted iNOS induction in MC (Fig. 8). Under our conditions,
cyclohexenone was a more potent inhibitor than cyclopen-
tenone and completely abrogated cytokine-elicited iNOS lev-
els at all concentrations assayed (50 to 200 M, not shown).
Effect of 15d-PGJ2 on the Levels of COX-2 and ICAM-1
in MC. To assess the significance of these findings, we next
explored the modulation of two additional proteins that play
key roles in glomerular inflammation, COX-2 and ICAM-1. As
observed with iNOS, treatment of MC with 15d-PGJ2 before
stimulation with cytokines strongly inhibited the induction of
COX-2 and ICAM-1 (62  10% and 79  13% inhibition, aver-
Fig. 3. Protein modification by biotinylated 15d-PGJ2 in intact cells and
in cell lysates. A, MC were incubated with increasing concentrations of
15d-PGJ2 or biotinylated 15d-PGJ2, and biotin-containing polypeptides in
total cell lysates were detected by Western blot. To visualize faint bands,
ECL exposures were carried out for 2 min. To show all the experimental
conditions in the same exposure without saturating the signal, 2 g of
protein was loaded onto lane 7, 5 g on lane 5, and 10 g on the
remaining lanes. B, MC lysates containing 6 g of protein were incubated
for 1 h at r.t. with vehicle, 10 M biotinylated 15d-PGJ2, or 2 mM
biotinylated iodoacetamide, as indicated. Aliquots containing 6 g (lanes
1, 2, and 5) or 0.6 g of protein (lanes 3 and 4) were analyzed by
SDS-PAGE, and biotin-containing polypeptides were detected by West-
ern blot. Lane 5 shows the Coomassie staining of a blot run in parallel.
Results shown are representative of three independent experiments. C,
the blots shown in B were quantitated after image scanning, and the
profiles obtained for each lane are shown. Results are expressed in
arbitrary units.
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age  S.E.M. of five and four assays, respectively, p  0.05 in
both cases) (Fig. 9). It is remarkable that the 9,10-dihydro
analog of 15d-PGJ2 not only did not reduce COX-2 induction but
also potentiated it (4.1 0.8-fold amplification of cytokine stim-
ulation, n  6), whereas it did not affect ICAM-1 (Fig. 9A).
Neither the inhibitory effect of 15d-PGJ2 nor the amplifying
effect of 9,10-dihydro-15d-PGJ2 on COX-2 levels was reduced in
the presence of the PPAR antagonist GW9662. Both cyclopen-
tenone and cyclohexenone inhibited COX-2 and ICAM-1 induc-
tion by cytokines. The inhibition of COX-2 induction by cyclo-
pentenone reached 51 10%, average S.E.M. of three assays,
p  0.05 by t test. Cyclohexenone completely abrogated COX-2
induction (Fig. 9B). Cyclopentenone inhibited cytokine-elicited
ICAM levels by 66  13%, average  S.E.M. of three assays,
p  0.05. Treatment with cyclohexenone before cytokine stim-
ulation reduced ICAM protein below basal levels. These results
strengthen our hypothesis that the reactivity of 15d-PGJ2 to-
ward cellular thiols is important for its anti-inflammatory ef-
fects.
Discussion
CyPG, and 15d-PGJ2 in particular, have attracted consid-
erable attention recently because of their remarkable biolog-
ical effects. 15d-PGJ2 has been reported to exert anti-inflam-
matory or protective effects in both cellular and animal
models of inflammation or injury. These effects were first
attributed to its activity as an agonist of the transcription
factor PPAR. However, it is becoming gradually more ac-
cepted that an important determinant of 15d-PGJ2 activity
resides in its cyclopentenone structure, capable of forming
covalent adducts with thiol groups by Michael addition. In
this study, we have observed that 15d-PGJ2 binds to multiple
but selective protein targets in MC and that the presence of
the cyclopentenone moiety is important both for protein mod-
ification and for inhibition of the levels of pro-inflammatory
proteins.
In light of recent in vitro and in vivo studies, a potential for
cyPG or related compounds as pharmacological tools in the
treatment of inflammatory conditions has been raised. Some
recent examples of the beneficial effects of cyPG include the
amelioration of acute renal failure (Chatterjee et al., 2004) and
the reduction of restenosis after balloon angioplasty in rats
(Ianaro et al., 2003b) by 15d-PGJ2, effects that have been at-
tributed to its ability to inhibit NF-B and the expression of
pro-inflammatory genes. However, the possibility that cyPG
may freely react with protein thiols may constitute a drawback
to their use in therapy because it could contribute to lack of
specificity or multiplicity of unwanted biological effects. The
experiments presented herein illustrate that covalent binding
of a biotinylated analog of 15d-PGJ2 to MC proteins is not
determined by protein abundance or simply by the presence of
accessible cysteine residues. This implies that the process of
protein modification by these products of the arachidonic acid
pathway, which could be referred to as eicosanylation or pros-
tanylation, displays a selectivity probably related to protein or
cellular context. By using two-dimensional electrophoresis, we
have observed that biotinylated 15d-PGJ2 binds to a broad but
limited set of proteins in intact cells. Although the possibility
that the reactivity of biotinylated 15d-PGJ2 may not be identi-
cal to that of 15d-PGJ2 should be taken into account, our observa-
tions provide a starting point for the identification and subsequent
functional studies of themodified proteins that will help to predict
the potential consequences of 15d-PGJ2 treatment.
The cyclopentenone moiety of 15d-PGJ2 has been proposed
as an important structural feature for some of the effects of
this cyPG (Straus et al., 2000; Ianaro et al., 2003a). The
9,10-dihydro analog of 15d-PGJ2 differs only in the absence of
the endocyclic double bond and is therefore not a cyclopen-
Fig. 4. MALDI-TOF mass spectrometry analysis of the
interaction between c-Jun and several PG. c-Jun con-
struct (5 M) was incubated with 10 M concentrations
of the indicated compounds for 1 h at r.t. and analyzed
by MALDI-TOF mass spectrometry. Results shown are
representative of three assays. The structure of the
compounds used is shown on the right. Electrophilic
carbons are marked by asterisks.
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tenone. This compound, designed as an analog of 15d-PGJ2
unable to undergo conjugation with glutathione across car-
bon 9, has been previously proposed as a tool to explore the
importance of conjugation with thiols in the effect of 15d-
PGJ2 (Cippitelli et al., 2003; Paumi et al., 2003). However,
the ability of 9,10-dihydro-15d-PGJ2 to form adducts with
proteins has not been explored. Our results indicate that
9,10-dihydro-15d-PGJ2 still retains the ability to form cova-
lent adducts with proteins, as observed in vitro using a frag-
ment of c-Jun as a model. This suggests that other electro-
philic carbons present in the molecule of 15d-PGJ2, such as
carbon 13, may also participate in the formation of Michael
adducts with proteins. This hypothesis is in agreement with
previous reports that have identified the formation of bis-
conjugates of 15d-PGJ2 with c-Jun (Pe´rez-Sala et al., 2003)
and of 9-deoxy-9,12(E)-PGD2, a cyPG that also possesses
two electrophilic carbons, with glutathione (Atsmon et al.,
1990). Nevertheless, our results suggest that 9,10-dihydro-
15d-PGJ2 shows reduced potency as a cysteine-modifying
agent, as deduced from its lesser ability to block the incorpo-
ration of biotinylated iodoacetamide or biotinylated 15d-
PGJ2 into both recombinant proteins and cellular lysates.
Consistent with this, in conditions under which 9,10-dihydro-
15d-PGJ2 and 15d-PGJ2 were equipotent at activating a
PPRE reporter, 9,10-dihydro-15d-PGJ2 did not mimic the
marked inhibitory effect of 15d-PGJ2 on the levels of iNOS,
COX-2, or ICAM-1. However, a moderate inhibitory effect
could be evidenced with concentrations of 9,10-dihydro-15d-
PGJ2 above 20 M (results not shown). Taken together, these
observations suggest that the cyclopentenone structure of
15d-PGJ2 is an important determinant both in the inhibition
of the induction of pro-inflammatory genes and in the ability
of 15d-PGJ2 to modify cellular proteins. However, 15d-PGJ2
analogs retaining electrophilic carbons cannot be considered
inert compounds with respect to cysteine modification, and
care should be exercised when using them as a control for the
actions of cyPG.
CyPG have been shown to inhibit the induction of various
pro-inflammatory genes in several experimental systems.
However, the mechanisms responsible for this effect may be
multiple and seem to be dependent on the system under
study. An involvement of PPAR has been proposed in cyPG-
mediated inhibition of IL-1-elicited iNOS induction in car-
Fig. 5. Effect of several PG on the binding of biotinylated iodoacetamide
or biotinylated 15d-PGJ2 to c-Jun or cell lysates in vitro. A, c-Jun con-
struct was preincubated with the indicated PG at 100 M final concen-
tration or 2 mM iodoacetamide for 1 h at r.t. and subsequently incubated
in the presence of 2 mM biotinylated iodoacetamide for 30 min. B, c-Jun
was incubated with 1 M biotinylated 15d-PGJ2 for 1 h at r.t. in the
absence or presence of 100 M of the indicated compounds. C, aliquots
from total cell lysates containing 6 g of protein were incubated with 10
M biotinylated 15d-PGJ2 in the presence of 1 mM concentrations of the
indicated PG. Incubation mixtures were subjected to SDS-PAGE and
Western blot followed by detection with HRP-conjugated streptavidin or
anti-c-Jun antibody, as indicated. Exposures shown are representative of
at least three experiments with similar results for every assay.
Fig. 6. Effect of 15d-PGJ2 and 9,10–15d-PGJ2 on the activity of a PPRE
reporter. MC were transiently transfected with p4xAco-Luc plus pSG5-
Renilla and treated for 16 h with the indicated concentrations of 15d-
PGJ2 or 9,10-dihydro-15d-PGJ2 (A) or with 100 M cyclopentenone, 100
M cyclohexenone, 5 M rosiglitazone, 1 M T0070907, or 5 M 9,10-
dihydro-15d-PGJ2, as indicated (B). Results are expressed as the ratio
between firefly and R. reniformis luciferase activities. Results are aver-
age values  S.E.M. of three independent experiments performed in
duplicate. (*, p  0.05 versus control by t test; #, p  0.05 versus
rosiglitazone).
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diomyocytes (Mendez and LaPointe, 2003) and in human
chondrocytes (Fahmi et al., 2001), as well as in the modula-
tion of myeloperoxidase by 15d-PGJ2 (Kumar et al., 2004)
and in the protective effects of this cyPG in endotoxemia
(Collin et al., 2004) and ischemia-reperfusion injury (Cuzzo-
crea et al., 2003). In contrast, PPAR-independent mecha-
nisms have been invoked for the inhibitory actions of 15d-
PGJ2 on the expression of iNOS in pancreatic -cells and in
IFN-induced macrophages (Chen et al., 2003; Weber et al.,
2004), for the inhibition of NF-B and AP-1 in cells express-
ing undetectable levels of PPAR, such as HeLa cells (Straus
et al., 2000; Pe´rez-Sala et al., 2003), and for some of the in
vivo anti-inflammatory effects (Ianaro et al., 2003a). The
effect of 15d-PGJ2 on iNOS induction in MC and the mech-
anisms involved have not been previously addressed. Our
results suggest that in MC the inhibition of cytokine-elicited
Fig. 7. Effect of 15d-PGJ2 on iNOS induction is independent from PPAR
activity. A, MC were preincubated for 2 h with the indicated PPAR
agonists at 5 M before stimulation with IL-1 plus TNF- (Ck). B, MC
were pretreated with 10 M GW9662 before addition of 15d-PGJ2. C, MC
were preincubated with 1 M T0070907 before addition of 5 M rosigli-
tazone. After 16 h of treatment with cytokines, the accumulation of nitrite
in the cell supernatant was measured by the Griess method. Results are
average values  S.E.M. of three experiments (*, p  0.05 versus Ck by
t test). Levels of iNOS and actin in MC extracts were assessed by Western
blot. ECL exposures are representative of three experiments with similar
results.
Fig. 8. Cyclopentenone and cyclohexenone inhibit iNOS induction. MC
were pretreated with 100 M cyclopentenone or cyclohexenone for 2 h
before stimulation with Ck. Levels of nitrite in the cell supernatants and
of iNOS protein and actin in cell lysates were assessed as in Fig. 7.
Results are average values  S.E.M. of three experiments (*, p  0.05
versus Ck by t test). ECL exposures are representative of three experi-
ments with similar results. The structure of the compounds used is shown
on the right. Electrophilic carbons are marked by asterisks.
Fig. 9. Effect of several electrophilic compounds on the expression of
COX-2 and ICAM-1 in MC. MC were pretreated with the indicated
compounds, as specified in Fig. 7 and 8, before stimulation with Ck, and
the protein levels of COX-2, ICAM-1, and actin were assessed by Western
blot. ECL exposures are representative of three experiments with similar
results.
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iNOS induction is largely independent of PPAR activation.
This inference is based on the fact that 15d-PGJ2 and its
9,10-dihydro analog have different effects on iNOS induction
but are equally potent as PPAR agonists, on the lack of effect
of the PPAR antagonist GW9662 on 15d-PGJ2-elicited inhi-
bition, and on the inhibitory effect of other electrophiles, such
as cyclopentenone and cyclohexenone. In addition, the
PPAR ligand rosiglitazone increased iNOS levels rather
than reducing them. This observation is also supported by
previous results from our laboratory showing that other
PPAR agonists amplify cytokine-elicited iNOS induction
(Cernuda-Morollo´n et al., 2002). It is interesting that the
inhibition of the induction of two additional pro-inflamma-
tory genes, such as COX-2 and ICAM-1, also requires the
presence of the endocyclic double bond of 15d-PGJ2. It is
remarkable that the absence of this bond, as it occurs in the
9,10-dihydro analog of 15d-PGJ2, results in a strong poten-
tiation of COX-2 induction. The elucidation of the mechanism
of this effect, which is not blocked by GW9662, will require
further investigation.
In conclusion, the observations described above point to the
importance of covalent protein modification in the anti-in-
flammatory effects of 15d-PGJ2. Our work illustrates the
requirements, extent and selectivity of protein modification
by 15d-PGJ2 in MC. The identification of the detected targets
for cyPG addition will provide a deeper insight into the mech-
anism of action and potential applications of these eico-
sanoids.
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